Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gee

Showing results (131-140 of 419) with videos related to

Pageof 42
Sort By:
Cytotherapy|June 8, 2010
Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experienceAdrian P Gee, Sara Richman, April Durett, et al.
Blood|July 13, 2006
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Barbara Savoldo, John A Goss, Markus M Hammer, et al.
Blood|October 27, 2005
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantationRaphaël F Rousseau, Ettore Biagi, Aurélie Dutour, et al.
Blood|January 30, 2010
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantationKenneth P Micklethwaite, Barbara Savoldo, Patrick J Hanley, et al.
Blood|August 25, 2009
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantationAnn M Leen, Anne Christin, Gary D Myers, et al.
American Heart Journal|December 6, 2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationaleClaudia Zierold, Marjorie A Carlson, Udo C Obodo, et al.
The Journal of Clinical Investigation|August 15, 2017
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytesCarlos A Ramos, Brandon Ballard, Huimin Zhang, et al.
The Journal of Clinical Investigation|June 9, 2016
Clinical responses with T lymphocytes targeting malignancy-associated κ light chainsCarlos A Ramos, Barbara Savoldo, Vicky Torrano, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Optimizing the production of suspension cells using the G-Rex "M" seriesPradip Bajgain, Roopa Mucharla, John Wilson, et al.
Blood|May 16, 2009
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopesPatrick J Hanley, Conrad Russell Young Cruz, Barbara Savoldo, et al.
Pageof 42

Showing results (131-140 of 419) with videos related to

Sort By:
Pageof 42
Cytotherapy|June 8, 2010
Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experienceAdrian P Gee, Sara Richman, April Durett, et al.
Blood|July 13, 2006
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Barbara Savoldo, John A Goss, Markus M Hammer, et al.
Blood|October 27, 2005
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantationRaphaël F Rousseau, Ettore Biagi, Aurélie Dutour, et al.
Blood|January 30, 2010
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantationKenneth P Micklethwaite, Barbara Savoldo, Patrick J Hanley, et al.
Blood|August 25, 2009
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantationAnn M Leen, Anne Christin, Gary D Myers, et al.
American Heart Journal|December 6, 2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationaleClaudia Zierold, Marjorie A Carlson, Udo C Obodo, et al.
The Journal of Clinical Investigation|August 15, 2017
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytesCarlos A Ramos, Brandon Ballard, Huimin Zhang, et al.
The Journal of Clinical Investigation|June 9, 2016
Clinical responses with T lymphocytes targeting malignancy-associated κ light chainsCarlos A Ramos, Barbara Savoldo, Vicky Torrano, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Optimizing the production of suspension cells using the G-Rex "M" seriesPradip Bajgain, Roopa Mucharla, John Wilson, et al.
Blood|May 16, 2009
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopesPatrick J Hanley, Conrad Russell Young Cruz, Barbara Savoldo, et al.
Pageof 42